Subscribe To Our Free Newsletter |
Strides rallies 9% intraday, hits over 3 year high on healthy Q4 results
Strides Pharma stock price: For FY25, Strides said revenue may grow at 12-15 per cent Y-o-Y and the significant growth will come in H2FY25 based on targeted product launches globally